Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 3 Ovarian Neoplasms 2 Neoplasm Metastasis 2 Triple Negative Breast Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Neoplasms 1 Meningioma 1 Malignant Female Reproductive System Neoplasm 1 Hemangiosarcoma 1 Fallopian Tube Neoplasms 1 Ependymoma 1 Endometrial Neoplasms 1 Disease Progression 1 Colonic Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

Cisplatin 15 Gemcitabine 14 durvalumab 9 pembrolizumab 7 Oxaliplatin 6 Bevacizumab 6 Capecitabine 5 lenvatinib 4 S 1 (combination) 3 Liquid Biopsy 3 Irinotecan 3 Folfox protocol 3 Fluorouracil 3 Carboplatin 3 zanidatamab 2 tremelimumab 2 envafolimab 2 Trastuzumab 2 Nivolumab 2 Leucovorin 2 Injections 2 Blood Specimen Collection 2 Albumin-Bound Paclitaxel 2 trastuzumab deruxtecan 1 toripalimab 1 tislelizumab 1 poly ICLC 1 niraparib 1 neratinib 1 larotrectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × neratinib × 90 days × Clear all

NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡